To save lives through rigorous science, data-driven decision making, and innovative medicines.


We are a clinical-stage immunotherapy company engaged in the discovery and development of next generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage™ platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.

Our lead program, SNS-301, targets the tumor antigen, Aspartyl beta Hydroxylase (ASPH), and is in an ongoing Phase 1/2 trial in combination with pembrolizumab for the treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Additional programs are in various stages of preclinical development.

Located in Rockville, Maryland and Boston, Massachusetts, we have state-of-the-art laboratories for discovery, development, and manufacturing of biological products, as well as clinical testing.